Nanjing Leads Biolabs Receives CDE Approval for Phase III Trial of Opamtistomig (LBL-024) in Advanced Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Nanjing Leads Biolabs Announces Major Clinical Milestone for...
Sign in to continue:
Nanjing Leads Biolabs Announces Major Clinical Milestone for...
UISEE Technologies: Investor Guidance on Shareholder Directo...
TransThera Sciences (Nanjing), Inc. Announces HK\$156.62 Mil...
Jacobio Pharmaceuticals Announces Robust Share Repurchase Pr...
Zhejiang Taimei Medical Technology Co., Ltd. - EGM Notice: S...
China Ruyi Holdings Limited Announces Share and Convertible ...
WuXi XDC Cayman Inc. Announces US\$100 Million Share Purchas...
APT Electronics Co., Ltd. Announces Extraordinary General Me...
VOYAH Automotive Technology Co., Ltd. - CSRC Accepts Filing ...
King’s Stone Holdings Announces Strategic Investment in New ...